AUA 2021: Pembrolizumab Is a Potential New Standard of Care for RCC in the Adjuvant Setting
Effective therapy to reduce risk of relapse after surgery remains an unmet need
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.